Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned an average rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $50.6667.

Several brokerages have recently issued reports on ORKA. BTIG Research lifted their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Guggenheim assumed coverage on Oruka Therapeutics in a report on Monday, October 27th. They set a “buy” rating and a $60.00 target price on the stock. Wedbush upped their price target on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Barclays began coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective on the stock. Finally, HC Wainwright cut their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 27th.

Oruka Therapeutics Stock Down 2.9%

Shares of ORKA opened at $34.23 on Friday. The firm has a market capitalization of $1.66 billion, a PE ratio of -18.02 and a beta of -0.39. The firm has a 50-day moving average price of $30.93 and a 200 day moving average price of $23.51. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $36.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. On average, equities analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total value of $222,670.00. Following the transaction, the insider directly owned 1,518 shares in the company, valued at $48,287.58. The trade was a 82.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 24.69% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $31,000. BNP Paribas Financial Markets lifted its position in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Finally, Russell Investments Group Ltd. purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.